Redfin (RDFN) Reaches $21.88 After 6.00% Down Move; 7 Analysts Are Bullish TG Therapeutics (TGTX) Last Week

November 8, 2017 - By Darrin Black

The stock of Redfin Corp (NASDAQ:RDFN) is a huge mover today! About 654,042 shares traded or 9.39% up from the average. Redfin Corp (NASDAQ:RDFN) has 0.00% since November 8, 2016 and is . It has underperformed by 16.70% the S&P500.The move comes after 6 months negative chart setup for the $1.76B company. It was reported on Nov, 8 by Barchart.com. We have $20.57 PT which if reached, will make NASDAQ:RDFN worth $105.60M less.

Among 7 analysts covering TG Therapeutics (NASDAQ:TGTX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 11 analyst reports since August 12, 2015 according to SRatingsIntel. H.C. Wainwright maintained TG Therapeutics Inc (NASDAQ:TGTX) on Tuesday, March 7 with “Buy” rating. The company was maintained on Monday, June 5 by Jefferies. FBR Capital maintained the shares of TGTX in report on Thursday, June 15 with “Buy” rating. Brean Capital reinitiated the shares of TGTX in report on Thursday, October 6 with “Buy” rating. Zacks upgraded the stock to “Hold” rating in Wednesday, August 12 report. SunTrust initiated the shares of TGTX in report on Friday, May 27 with “Buy” rating. The rating was initiated by Suntrust Robinson on Friday, May 27 with “Buy”. As per Wednesday, August 12, the company rating was reinitiated by H.C. Wainwright. Raymond James initiated TG Therapeutics Inc (NASDAQ:TGTX) on Wednesday, September 9 with “Strong Buy” rating. FBR Capital initiated TG Therapeutics Inc (NASDAQ:TGTX) rating on Tuesday, December 1. FBR Capital has “Outperform” rating and $29 target. See TG Therapeutics Inc (NASDAQ:TGTX) latest ratings:

18/10/2017 Broker: SunTrust Rating: Buy
15/06/2017 Broker: FBR Capital Rating: Buy Maintain
05/06/2017 Broker: Jefferies Rating: Buy New Target: $23.0000 Maintain

TG Therapeutics, Inc. is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has market cap of $530.04 million. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. It currently has negative earnings. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Since June 16, 2017, it had 0 insider purchases, and 1 insider sale for $665,133 activity. Power Sean A also sold $665,133 worth of TG Therapeutics Inc (NASDAQ:TGTX) shares.

Investors sentiment increased to 2.28 in 2017 Q2. Its up 0.25, from 2.03 in 2017Q1. It increased, as 6 investors sold TG Therapeutics Inc shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 33.91 million shares or 12.20% more from 30.22 million shares in 2017Q1 were reported. Ubs Asset Mngmt Americas Incorporated invested 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). New York-based D E Shaw And Incorporated has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Credit Suisse Ag invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Alliancebernstein Lp has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Columbus Circle Investors holds 0.23% or 1.40 million shares in its portfolio. Gru One Trading L P stated it has 123,963 shares. Stoneridge Investment Prtnrs Ltd Liability Com has invested 0.16% in TG Therapeutics Inc (NASDAQ:TGTX). Ra Capital Management Lc holds 0.81% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 700,000 shares. Morgan Stanley owns 104,403 shares. The North Carolina-based Bancorporation Of America De has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). California State Teachers Retirement Sys, a California-based fund reported 85,935 shares. Dupont Mngmt has invested 0.01% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). Great West Life Assurance Can invested in 10,839 shares or 0% of the stock. Creative Planning holds 4,000 shares or 0% of its portfolio. Group Inc Inc has 30,102 shares.

The stock increased 1.99% or $0.15 during the last trading session, reaching $7.7. About 1.21 million shares traded. TG Therapeutics Inc (NASDAQ:TGTX) has risen 60.54% since November 8, 2016 and is uptrending. It has outperformed by 43.84% the S&P500.

Redfin Corporation is engaged in providing residential real estate brokerage services. The company has market cap of $1.76 billion. The customer can search for homes by neighborhood, city or MLS number, or can refine results using detailed parameters, such as price and number of beds or baths. It currently has negative earnings. The Firm serves home buyers and sellers.

Analysts await Redfin Corp (NASDAQ:RDFN) to report earnings on December, 7. RDFN’s profit will be $9.65M for 45.58 P/E if the $0.12 EPS becomes a reality. After $0.06 actual earnings per share reported by Redfin Corp for the previous quarter, Wall Street now forecasts 100.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Darrin Black




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: